Source - LSE Regulatory
RNS Number : 5452X
ReNeuron Group plc
01 September 2020
 

 

1 September 2020

AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Block Listing Review and Total Voting Rights

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

 

Name:

ReNeuron Group plc

Name of Scheme:

ReNeuron Share Option Schemes

Period of Return:

From 1 March 2020 to 31 August 2020

Balance of unallotted securities under scheme(s) from previous return:

715,241 Ordinary Shares (of 1p each)

 

Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):

N/A

Less: Number of securities issued/allotted under scheme(s) during period

40,554

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

674,687 Ordinary Shares

Number and class of securities originally admitted and the date of admission:

20,000 ordinary shares on 13 May 2010

 

 

Total Voting Rights

At 31 August 2020, the Company had 31,874,324 Ordinary Shares in issue, all with voting rights. This follows the issue of 26,120 new shares arising from the exercise of options by staff, such shares having been admitted under the above block listing arrangement.

 

As the Company holds no ordinary shares in treasury, the figure of 31,874,324 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

ENDS

 

ENQUIRIES:

 

ReNeuron

+44 (0) 20 3819 8400

Olav Hellebø , Chief Executive Officer


Michael Hunt, Chief Financial Officer


 

Buchanan (Media/Investor relations)

 

+44 (0) 20 7466 5000

Mark Court, Tilly Abraham




Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0) 20 7710 7600

N+1 Singer (Joint Broker)

Aubrey Powell, James Moat, Tom Salvesen

 

+44 (0) 20 7496 3000

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKKDBBFBKDKFN
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.